Company research
ASTRAZENECA PLC
CIK 901832Updated Nov 18, 2026
AZN price & chart
Loading TradingView…
NYSE:AZN on TradingView ↗In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN ↗
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossUSD | 2,448,000,000Source | 1,928,000,000Source | 1,820,000,000Source | 360,000,000Source | 550,000,000Source | 738,000,000Source | 107,000,000Source | 319,000,000Source | 10,233,000,000Source | 7,041,000,000Source | 5,961,000,000Source | 3,293,000,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodUSD | — | — | — | — | — | — | — | — | -60,000,000Source | -107,000,000Source | 28,000,000Source | -187,000,000Source |
| AdjustmentsForDeferredTaxOfPriorPeriodsUSD | — | — | — | — | — | — | — | — | -47,000,000Source | 23,000,000Source | -34,000,000Source | 135,000,000Source |
| AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | — | — | — | — | — | — | — | — | 5,733,000,000Source | 6,688,000,000Source | 5,387,000,000Source | — |
| AdjustmentsForSharebasedPaymentsUSD | — | — | — | — | — | — | — | — | 719,000,000Source | 660,000,000Source | 579,000,000Source | 619,000,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | — | — | — | — | — | — | 201,000,000Source | -193,000,000Source | 128,000,000Source | -590,000,000Source |
| DividendsPaidClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 4,971,000,000Source | 4,629,000,000Source | 4,481,000,000Source | 4,364,000,000Source |
| DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYearUSD | — | — | — | — | — | — | — | — | 1,597,000,000Source | 1,550,000,000Source | 1,440,000,000Source | 1,440,000,000Source |
| DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYearsUSD | — | — | — | — | — | — | — | — | 3,249,000,000Source | 3,052,000,000Source | 3,047,000,000Source | 3,046,000,000Source |
| GoodwillUSD | 21,222,000,000Source | 21,060,000,000Source | 19,960,000,000Source | 19,821,000,000Source | 11,798,000,000Source | 11,645,000,000Source | 11,668,000,000Source | 11,717,000,000Source | 21,242,000,000Source | 21,025,000,000Source | 20,048,000,000Source | 19,820,000,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | — | — | — | — | — | — | — | — | 2,845,000,000Source | 2,750,000,000Source | 2,366,000,000Source | 1,623,000,000Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | — | — | — | — | — | — | — | — | 1,316,000,000Source | 1,313,000,000Source | 1,081,000,000Source | 849,000,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 372,000,000Source | 316,000,000Source | 268,000,000Source | 244,000,000Source |
| PaymentsToAcquireOrRedeemEntitysSharesUSD | — | — | — | — | — | — | — | — | 521,000,000Source | 81,000,000Source | — | — |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | — | — | 15,000,000Source | 6,492,000,000Source | 3,816,000,000Source | — |
| ProceedsFromIssuingSharesUSD | — | — | — | — | — | — | — | — | 40,000,000Source | 38,000,000Source | 33,000,000Source | 29,000,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | — | — | — | — | — | — | — | — | 13,000,000Source | 55,000,000Source | 132,000,000Source | 282,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | — | — | — | — | — | 3,095,000,000Source | 2,662,000,000Source | 2,417,000,000Source | 1,480,000,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | — | 2,643,000,000Source | — | — | — | — | — | — | 2,029,000,000Source | 4,652,000,000Source | 4,942,000,000Source | 1,271,000,000Source |
income statement · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | 4,864,000,000Source | 4,929,000,000Source | 4,986,000,000Source | 4,681,000,000Source | 3,098,000,000Source | 2,635,000,000Source | 2,943,000,000Source | 2,551,000,000Source | 19,933,000,000Source | 19,977,000,000Source | 19,216,000,000Source | 18,419,000,000Source |
| Total RevenueUSD | 14,457,000,000Source | 12,938,000,000Source | 11,416,000,000Source | 10,771,000,000Source | 8,220,000,000Source | 6,275,000,000Source | 5,823,000,000Source | 5,155,000,000Source | 58,739,000,000Source | 54,073,000,000Source | 45,811,000,000Source | 44,351,000,000Source |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.25Source | 0.25Source | 0.24Source | 0.19Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | — | — | — | 0.18Source | 0.19Source | 0.14Source | -0.32Source |
| BasicEarningsLossPerShareUSD per share | 1.58Source | 1.24Source | 1.17Source | 0.23Source | 0.42Source | 0.58Source | 0.09Source | 0.27Source | 6.6Source | 4.54Source | 3.84Source | 2.12Source |
| CurrentTaxExpenseIncomeUSD | — | — | — | — | — | — | — | — | — | — | 2,417,000,000Source | 1,823,000,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD | — | — | — | — | — | — | — | — | -164,000,000Source | -795,000,000Source | -1,507,000,000Source | -2,428,000,000Source |
| DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossUSD | — | — | — | — | — | — | — | — | — | — | — | 5,480,000,000Source |
| DepreciationRightofuseAssetsUSD | — | — | — | — | — | — | — | — | 404,000,000Source | — | — | — |
| DilutedEarningsLossPerShareUSD per share | 1.57Source | 1.24Source | 1.17Source | 0.23Source | 0.42Source | 0.58Source | 0.1Source | 0.27Source | 6.54Source | 4.5Source | 3.81Source | 2.11Source |
| EmployeeBenefitsExpenseUSD | — | — | — | — | — | — | — | — | 14,548,000,000Source | 13,709,000,000Source | 12,335,000,000Source | 11,531,000,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | — | — | — | — | — | — | — | — | 719,000,000Source | 660,000,000Source | — | — |
| FinanceCostsUSD | 439,000,000Source | 443,000,000Source | 431,000,000Source | 311,000,000Source | 326,000,000Source | 329,000,000Source | 361,000,000Source | 375,000,000Source | 1,694,000,000Source | 1,742,000,000Source | 1,626,000,000Source | 1,346,000,000Source |
| FinanceIncomeUSD | 68,000,000Source | 100,000,000Source | 64,000,000Source | 18,000,000Source | 7,000,000Source | 22,000,000Source | 41,000,000Source | 43,000,000Source | 360,000,000Source | 458,000,000Source | 344,000,000Source | 95,000,000Source |
| GrossProfitUSD | 11,984,000,000Source | 10,755,000,000Source | 9,456,000,000Source | 7,773,000,000Source | 6,029,000,000Source | 5,291,000,000Source | 4,760,000,000Source | 4,143,000,000Source | 48,106,000,000Source | 43,866,000,000Source | 37,543,000,000Source | 31,960,000,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | — | — | — | — | — | — | 230,000,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | 679,000,000Source | 469,000,000Source | 268,000,000Source | -113,000,000Source | 214,000,000Source | 223,000,000Source | 34,000,000Source | 93,000,000Source | 2,169,000,000Source | 1,650,000,000Source | 938,000,000Source | -792,000,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | — | — | — | — | — | — | 80,000,000Source | 61,000,000Source | 33,000,000Source | 24,000,000Source |
| NetForeignExchangeLossUSD | — | — | — | — | — | — | — | — | 31,000,000Source | 42,000,000Source | 34,000,000Source | 16,000,000Source |
| OtherEmployeeExpenseUSD | — | — | — | — | — | — | — | — | 1,608,000,000Source | 1,531,000,000Source | 1,357,000,000Source | 1,338,000,000Source |
| OtherOperatingIncomeExpenseUSD | 79,000,000Source | 60,000,000Source | 784,000,000Source | 122,000,000Source | 128,000,000Source | 121,000,000Source | 113,000,000Source | 617,000,000Source | 381,000,000Source | 252,000,000Source | 1,340,000,000Source | 514,000,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansUSD | — | — | — | — | — | — | — | — | 116,000,000Source | 136,000,000Source | — | — |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | — | — | — | — | — | — | — | — | 553,000,000Source | 528,000,000Source | 482,000,000Source | 445,000,000Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -2,000,000Source | 1,000,000Source | 2,000,000Source | — | — | -18,000,000Source | -23,000,000Source | -31,000,000Source | 8,000,000Source | 6,000,000Source | 6,000,000Source | 5,000,000Source |
| ProfitLossAttributableToOwnersOfParentUSD | 2,450,000,000Source | 1,927,000,000Source | 1,818,000,000Source | 360,000,000Source | 550,000,000Source | 756,000,000Source | 130,000,000Source | 350,000,000Source | 10,225,000,000Source | 7,035,000,000Source | 5,955,000,000Source | 3,288,000,000Source |
| ProfitLossBeforeTaxUSD | 3,127,000,000Source | 2,397,000,000Source | 2,088,000,000Source | 247,000,000Source | 764,000,000Source | 961,000,000Source | 141,000,000Source | 412,000,000Source | 12,402,000,000Source | 8,691,000,000Source | 6,899,000,000Source | 2,501,000,000Source |
| ProfitLossFromOperatingActivitiesUSD | 3,508,000,000Source | 2,746,000,000Source | 2,456,000,000Source | 539,000,000Source | 1,127,000,000Source | 1,284,000,000Source | 493,000,000Source | 763,000,000Source | 13,743,000,000Source | 10,003,000,000Source | 8,193,000,000Source | 3,757,000,000Source |
| ResearchAndDevelopmentExpenseUSD | 3,548,000,000Source | 3,008,000,000Source | 2,667,000,000Source | 2,546,000,000Source | 1,829,000,000Source | 1,389,000,000Source | 1,356,000,000Source | 1,362,000,000Source | 14,232,000,000Source | 13,583,000,000Source | 10,935,000,000Source | 9,762,000,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -10,000,000Source | -6,000,000Source | -1,000,000Source | 1,000,000Source | -44,000,000Source | -16,000,000Source | -32,000,000Source | -19,000,000Source | -7,000,000Source | -28,000,000Source | -12,000,000Source | -5,000,000Source |
Filing attachments
tm267648d3_ex4-1.htm · 6-K · 2026-03-02
Exhibit 4.1 ASTRAZENECA FINANCE LLC OFFICERS’ CERTIFICATE In connection with the issuance of the U.S.$650,000,000 4.000% Fixed Rate Notes due 2031 (the “2031 Notes”), the U.S.$600,000,000 4.300% Fixed Rate Notes due 2033 (the “2033 Notes”), the U.S.$750,000,000 4.600% Fixed Rate Notes due 2036 (the “2036 Notes” and, together with the 2031 Notes and the 2033 Notes, the “Notes” or the “Securities”) of AstraZeneca Finance LLC (the “Issuer”), in each case guaranteed by AstraZeneca PLC (the “Guaran…
Read attachment ↗tm265271d2_ex99-1.htm · SCHEDULE 13D/A · 2026-02-06
Exhibit 99.1 CUSIP No. 45781K105 Schedule I The name and present principal occupation of each of the executive officers and directors of AstraZeneca PLC are set forth below. Unless otherwise noted, each of these persons have as their business address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom. Name Position with AstraZeneca Principal Occupation and, if …
Read attachment ↗tm264269d1_ex4-2.htm · S-8 · 2026-02-02
Exhibit 4.2 Plan Rules of the AstraZeneca Restricted Share Plan Adopted by RemCo on 13 December 2023 and amended on 3 February 2025 and 11 December 2025. Plan terminates on 13 December 2033. French Appendix expires 13 April 2030 AstraZeneca Restricted Share Plan What is an award and when do you get shares? An award under the Plan is a contingent right to receive shares in AstraZeneca PLC. When your award 'vests' you receive shares. Your award will normally vest a specified number of years …
Read attachment ↗tm264269d1_ex4-3.htm · S-8 · 2026-02-02
Exhibit 4.3 Plan Rules of the AstraZeneca Global Restricted Stock Plan Adopted by RemCo on 1 March 2010 and restated on 22 October 2019 and amended on 25 September 2020, 27 April 2022, 13 December 2023, 3 February 2025, and 11 December 2025. Plan terminates on 22 October 2029 French Appendix restated by RemCo on 11 December 2025. AstraZeneca Global Restricted Stock Plan What is an ‘award’ and when do you get shares? An award under the Plan is a contingent right to receive shares in AstraZe…
Read attachment ↗tm264269d1_ex4-4.htm · S-8 · 2026-02-02
Exhibit 4.4 Plan Rules of the AstraZeneca Extended Incentive Plan Adopted by RemCo on 31 January 2018 and amended on 22 October 2019, 25 September 2020, 27 April 2022, 13 December 2023, 3 February 2025 and 11 December 2025. Plan terminates on 30 January 2028 Appendix 2 approved by RemCo on 23 July 2018 AstraZeneca Extended Incentive Plan What is an ‘award’ and when do you get shares? An award under the Plan is a contingent right to receive shares in AstraZeneca PLC. When your award ‘vests’ y…
Read attachment ↗tm264269d1_ex4-5.htm · S-8 · 2026-02-02
Exhibit 4.5 Plan Rules of the AstraZeneca Deferred Bonus Plan Adopted by RemCo on 21 August 2006, amended on 3 February 2014, 24 July 2017, 22 October 2019, 25 September 2020, 27 April 2022, 13 December 2023, 5 February 2024, 3 February 2025, and 11 December 2025 Plan terminates at discretion of RemCo Astrazeneca Deferred Bonus Plan What is an ‘award’ and when do you get shares? An award under the Plan is a contingent right to receive shares in AstraZeneca PLC. When your award ‘vests’ you re…
Read attachment ↗